Is Liver Cancer a Disease That Can Lead to Death? Looking at 2026 Survival Rates

Liver cancer is a cancer whose outcomes vary widely depending on stage and liver function, and not all patients die from it — based on Korean statistics for 2019–2023, the 5-year relative survival rate is 40.4%.

Key Summary

• Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registration Statistics 2019–2023, Korea Central Cancer Registry, National Cancer Center Korea).
• The U.S. SEER 5-year relative survival rate for liver and intrahepatic bile duct cancer is 21.9% (2016–2022); both figures are nationwide statistics, not results from any specific hospital.
• In liver cancer, not only the stage but also liver function grade (Child-Pugh) and portal pressure jointly determine whether treatment is feasible and what the prognosis will be.
• Survival rates are population averages, not predictions for any individual's outcome — even tumors of the same size can lead to different results depending on liver function.
• Different treatment pathways exist depending on stage, including resection, transplantation, locoregional therapy (radiofrequency ablation, embolization), and systemic drug therapy.

Why Is Liver Cancer Known as a Cancer With Mortality Risk?

• Liver cancer usually develops on top of a pre-existing liver disease such as chronic hepatitis or cirrhosis, so the issue is not only the progression of the cancer itself but also how much treatment the remaining liver function can tolerate. For this reason, even at the same stage, poor liver function can narrow treatment options and change outcomes.
• Staging systems for liver cancer (such as BCLC) jointly reflect three factors: the number and size of tumors and whether there is vascular invasion, the liver function grade, and overall performance status. Broadly, stages are divided into very early/early, intermediate, advanced, and terminal, with different recommended treatments for each. In the terminal stage, where liver function has deteriorated significantly, chemotherapy can actually further damage the liver, so the focus shifts to symptom control, preserving liver function, and reviewing the possibility of transplantation.

Does Early Detection Change Survival Rates?

• Korea has a national screening program that performs ultrasound and blood tests every 6 months for hepatitis B carriers and cirrhosis patients, resulting in a relatively high rate of detecting cancers while they are still small. This environment for early detection is explained as one of the background factors behind differences in national survival statistics.
• At the very early/early stage (small tumors, few in number, good liver function), liver resection is the first choice. If resection is difficult due to location or liver function, radiofrequency ablation is considered, and if liver function has deteriorated significantly but tumor size and number fall within certain criteria, liver transplantation is considered as a curative treatment.

Is Treatment Still Possible at Advanced Stages?

• Stage 1 (intermediate, multiple tumors within the liver) — Transarterial chemoembolization (TACE), which blocks the blood vessels feeding the tumor, is the central approach, sometimes combined with radioembolization, stereotactic body radiotherapy (SBRT), particle therapy, or systemic drug therapy.
• Stage 2 (advanced, vascular invasion or spread outside the liver) — Systemic drug therapy becomes central. Combining immune checkpoint inhibitors with angiogenesis inhibitors is now part of the first-line treatment standard, and oral targeted therapies may be used depending on the case.
• Stage 3 (significantly reduced liver function) — Because chemotherapy can further damage the liver, symptom control and preservation of liver function take priority.
• A key feature of liver cancer is that it often does not end with a single treatment; instead, the treatment sequence is adjusted and continued depending on how the situation evolves.

FAQ — Does Recurrence Risk Remain After Treatment?

Because liver cancer can newly develop in other parts of the liver beyond the treated area, follow-up intervals tend to be tighter than for other cancers. Typically, in the first 1–2 years after treatment, contrast-enhanced CT or MRI along with AFP testing are repeated every few months, with intervals gradually lengthened afterward. For patients with chronic hepatitis B or C, continuing antiviral treatment and liver function testing for life is common.

FAQ — Are These Survival Rates From a Specific Hospital?

No. Both the 40.4% figure (Korea) and the 21.9% figure (U.S. SEER) are nationwide statistics, not the results of any particular hospital. Under Korean medical law, hospital-specific outcome data is not used in advertising, and actual treatment results can vary from person to person depending on stage, liver function, and individual patient condition.

Sources and Notes

• This article was written based on National Cancer Registration Statistics 2019–2023 (Korea Central Cancer Registry, National Cancer Center Korea) and SEER 2016–2022 (U.S. National Cancer Institute).
• This content is intended for general medical information purposes only; diagnosis, treatment methods, and outcomes may vary depending on individual condition. Accurate diagnosis and treatment should always be determined through consultation with medical professionals.